ropinirole has been researched along with Disruptive, Impulse Control, and Conduct Disorders in 16 studies
Disruptive, Impulse Control, and Conduct Disorders: Disorders whose essential features are the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the individual or to others. Individuals experience an increased sense of tension prior to the act and pleasure, gratification or release of tension at the time of committing the act.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study confirms an association between aripiprazole, pramipexole, or ropinirole and impulse control disorder and gambling disorder." | 7.85 | Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. ( Carleton, BC; Etminan, M; Guo, M; Procyshyn, RM; Samii, A; Sodhi, M, 2017) |
| "Our study confirms an association between aripiprazole, pramipexole, or ropinirole and impulse control disorder and gambling disorder." | 3.85 | Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. ( Carleton, BC; Etminan, M; Guo, M; Procyshyn, RM; Samii, A; Sodhi, M, 2017) |
| "Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use." | 1.43 | A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. ( Antonini, A; Chaudhuri, KR; Durner, G; Falup-Pecurariu, C; Grilo, M; Henriksen, T; Kessel, B; Martinez-Martin, P; Odin, P; Rizos, A; Røkenes Karlsen, K; Sauerbier, A; Silverdale, M; Weintraub, D, 2016) |
| "To determine the frequency of impulse control disorders (ICDs) with the use of dopaminergic agents in restless legs syndrome (RLS)." | 1.36 | Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. ( Cornelius, JR; Frerichs, CF; Silber, MH; Slocumb, NL; Tippmann-Peikert, M, 2010) |
| "Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17." | 1.36 | Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. ( Koester, J; Lang, AE; Potenza, MN; Siderowf, AD; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, N | 1 |
| Bortolato, M | 1 |
| Castro-Martínez, XH | 1 |
| García-Ruiz, PJ | 2 |
| Martínez-García, C | 1 |
| Martínez-Castrillo, JC | 1 |
| Vela, L | 2 |
| Mata, M | 2 |
| Martínez-Torres, I | 1 |
| Feliz-Feliz, C | 1 |
| Palau, F | 1 |
| Hoenicka, J | 1 |
| Lee, JY | 1 |
| Jeon, B | 1 |
| Koh, SB | 1 |
| Yoon, WT | 1 |
| Lee, HW | 1 |
| Kwon, OD | 1 |
| Kim, JW | 1 |
| Kim, JM | 1 |
| Ma, HI | 1 |
| Kim, HT | 1 |
| Baik, JS | 1 |
| Cho, J | 1 |
| Wilson, L | 1 |
| Sheehan, J | 1 |
| Thorpe, M | 1 |
| Launois, C | 1 |
| Leu-Semenescu, S | 1 |
| Brion, A | 1 |
| Arnulf, I | 1 |
| Martinez Castrillo, JC | 1 |
| Alonso-Canovas, A | 1 |
| Herranz Barcenas, A | 1 |
| Sanchez Alonso, P | 1 |
| Olmedilla Gonzalez, N | 1 |
| Mahillo Fernandez, I | 1 |
| Rizos, A | 1 |
| Sauerbier, A | 1 |
| Antonini, A | 1 |
| Weintraub, D | 3 |
| Martinez-Martin, P | 1 |
| Kessel, B | 1 |
| Henriksen, T | 1 |
| Falup-Pecurariu, C | 1 |
| Silverdale, M | 1 |
| Durner, G | 1 |
| Røkenes Karlsen, K | 1 |
| Grilo, M | 1 |
| Odin, P | 2 |
| Chaudhuri, KR | 1 |
| Etminan, M | 1 |
| Sodhi, M | 1 |
| Samii, A | 1 |
| Procyshyn, RM | 1 |
| Guo, M | 1 |
| Carleton, BC | 1 |
| Weber, WE | 1 |
| Nijssen, PC | 1 |
| Cornelius, JR | 1 |
| Tippmann-Peikert, M | 1 |
| Slocumb, NL | 1 |
| Frerichs, CF | 1 |
| Silber, MH | 1 |
| Bienfait, KL | 1 |
| Menza, M | 1 |
| Mark, MH | 1 |
| Dobkin, RD | 1 |
| Koester, J | 1 |
| Potenza, MN | 2 |
| Siderowf, AD | 2 |
| Stacy, M | 1 |
| Voon, V | 1 |
| Whetteckey, J | 1 |
| Wunderlich, GR | 1 |
| Lang, AE | 1 |
| Ahlskog, JE | 1 |
| Dorfman, BJ | 1 |
| Nirenberg, MJ | 1 |
| Nissen, T | 1 |
| Newman, EJ | 1 |
| Grosset, KA | 1 |
| Daghem, M | 1 |
| Pal, G | 1 |
| Stewart, M | 1 |
| Macphee, GJ | 1 |
| Grosset, DG | 1 |
| Goveas, J | 1 |
| Morales, KH | 1 |
| Duda, JE | 1 |
| Moberg, PJ | 1 |
| Stern, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement[NCT01683253] | Phase 4 | 150 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents ([NCT00617019] | 3,234 participants (Actual) | Observational | 2006-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ropinirole and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine A | 2011 |
1 trial available for ropinirole and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Co | 2019 |
14 other studies available for ropinirole and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Disruptive, Impulse Control, and Conduct Disorders | 2020 |
Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
Topics: Adult; Age of Onset; Aged; Behavior, Addictive; Disruptive, Impulse Control, and Conduct Disorders; | 2018 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse C | 2013 |
Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.
Topics: Aged, 80 and over; Benzothiazoles; Depressive Disorder, Major; Disruptive, Impulse Control, and Cond | 2013 |
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Antiparkinson Agents; Benzothiaz | 2014 |
A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; | 2016 |
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Canada; Case-Control Studies; Cohort Stud | 2017 |
[Impulse control disorder induced by the use of dopamine agonists].
Topics: Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Indol | 2009 |
Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
Topics: Adult; Aged; Benzothiazoles; Case-Control Studies; Cross-Sectional Studies; Disruptive, Impulse Cont | 2010 |
Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
Topics: Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine A | 2010 |
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Binge-Eating Disorder; Comorbidity; Cross-Sectional Stud | 2010 |
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Topics: Aged; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles | 2013 |
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Confidence Intervals; Disorders of Excessive Somnolence; | 2012 |
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; | 2006 |